Bonaventure J, Nigam V N, Brailovsky C A
J Biol Response Mod. 1985 Jun;4(3):258-63.
Several protocols employing a new immunoadjuvant, maltose tetrapalmitate (MTP), were tried in an effort to obtain immunization against a weakly immunogenic transplantable mammary adenocarcinoma, 13762, in syngeneic Fischer rats. Effectiveness of immunization was measured by rejection of tumor or reduction in tumor growth, by alteration in survival time after tumor challenge, and by proliferation in vitro of spleen cells of animals tumor-sensitized by killed tumor cells and tumor extracts. No success in the induction of tumor rejection was achieved by employing killed tumor cells or 3 M KCl tumor extracts used in either the presence or absence of MTP. Only a low dose of viable tumor cells elicited tumor rejection immunity when combined with MTP treatment given three times weekly. Spleen cell proliferation of tumor-sensitized animals was obtained in the case of live cells and 3 M KCl extract immunization, and was specific for the type of antigen (killed cells or soluble) preparation employed.
为了在同基因的Fischer大鼠中获得针对弱免疫原性可移植乳腺腺癌13762的免疫，尝试了几种采用新型免疫佐剂麦芽四棕榈酸酯（MTP）的方案。通过肿瘤排斥或肿瘤生长的减少、肿瘤攻击后存活时间的改变以及用灭活肿瘤细胞和肿瘤提取物致敏的动物脾细胞的体外增殖来衡量免疫效果。无论有无MTP，使用灭活肿瘤细胞或3M KCl肿瘤提取物都未能成功诱导肿瘤排斥。只有低剂量的活肿瘤细胞与每周三次的MTP治疗联合使用时，才引发肿瘤排斥免疫。在活细胞和3M KCl提取物免疫的情况下，获得了肿瘤致敏动物的脾细胞增殖，并且对所用抗原（灭活细胞或可溶性）制剂的类型具有特异性。
